Etid klinik pou Limfom nan Washington
12 etid pou Limfom ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07015242A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
- Seattle Children s Hospital, Seattle
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT05237986A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Fred Hutch Cancer Center, Seattle
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06528301DALY II USA/ MB-CART2019.1 for DLBCL
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- University of Washington Medical Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Oct 14, 2025 · NCT06520098Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.